ReviewInternational journal of hematology2023
Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.
Review in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 26 citations in OpenAlex.
- Bone Marrow Microenvironment Drives Mature Neutrophil to a CD83International journal of cancer · 2026Article
- Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.The FEBS journal · 2026Review
- Clinical Evaluation of Ex Vivo Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed/Refractory Multiple Myeloma.Cancer research communications · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes.Blood cancer journal · 2026Review
- Machine Learning Model Predicts Monoclonal Gammopathy Using Routine Laboratory Values.JCO clinical cancer informatics · 2026Article
- Mechanisms and intervention strategies of microenvironment-mediated drug resistance in multiple myeloma.Cancer cell international · 2026Review
- Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study.Frontiers in medicine · 2026Article
- Case Report: A diagnostic chameleon of EBV-associated immune dysregulation: HLH unmasking multiple myeloma with subsequent emergence of aggressive B-cell lymphoma.Frontiers in immunology · 2026Article
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- Collision Tumors Involving Metastatic Carcinoma and Plasma Cell Myeloma: Report of Two Cases.Case reports in pathology · 2026Article
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- InhibitingBiomedicines · 2025Article
- Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.Targeted oncology · 2025Review
- Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma.Blood advances · 2025Article
- SARS-CoV-2 Vaccine-Induced Seroconversion and Immune Correlates in Patients with Hematological Malignancies. A Real World Study.Oncology research · 2025Article
- Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.Advances in hematology · 2025Article
- Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients.American journal of translational research · 2025Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune dysregulation is a hallmark of clinically active multiple myeloma (MM). Interactions between malignant clonal cells and immune cells within the bone marrow microenvironment are associated with the formation of a milieu favorable to tumor progression. IL-10, TGF-β and other immunoregulatory pathways are upregulated, promoting angiogenesis, tumor cell survival and inhibition of the native immune response. Transcriptomic evaluation of the bone marrow microenvironment reveals polarization of the T cell repertoire towards exhaustion and predominance of accessory cells with immunosuppressive qualities. These changes facilitate the immune escape of tumor cells and functional deficiencies that manifest as an increased risk of infection and a reduction in response to vaccinations. Immunotherapy with Chimeric Antigen Receptor (CAR) T cells and other cellular-based approaches have transformed outcomes for patients with advanced MM. Characterization of the immune milieu and identification of biomarkers predictive of treatment response are essential to increasing durability and allowing for the incorporation of novel strategies such as cancer vaccines. This paper will review the current use of cancer vaccines and CAR T cell therapy in MM as well as potential opportunities to expand and improve the application of these platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.